Healthcare Industry News: Vbeam laser
News Release - April 4, 2007
Vbeam(R) Laser Provides Safe and Effective Treatment for Debilitating Skin DisorderCandela Lasers Celebrates 15 Years of Helping Rosacea Sufferers
WAYLAND, Mass.--(HSMN NewsFeed)--During Rosacea Awareness Month this April, sponsored by the National Rosacea Society, patients are urged to learn more about effective treatment alternatives now available to help them cope with the serious side effects of this chronic skin condition. The use of Candela's Vbeam® laser is a preferred treatment among doctors, and is among the treatment options described by the National Rosacea Society. Vbeam's exclusive micropulse technology provides quick, consistent results and patients appreciate that Vbeam treatments are safe and easy, with little downtime in comparison to topical treatments or oral antibiotics.
According to a recent Gallup survey, 78 percent of Americans have no knowledge of what rosacea is, including how to recognize it and what to do about it. Rosacea is a skin disorder causing redness, visible facial veins and small, pus filled bumps on the face, usually on the cheeks and nose. It is estimated that 14 million Americans have rosacea. Many experience low self-esteem, and tend to avoid public contact, canceling social engagements because of emotional and physical torment of the disease. However, with today's medical advances, including Candela's Vbeam pulsed dye laser, the redness, appearance of blood vessels, and flushing that occur with rosacea can be removed and effectively controlled. Vbeam treatments allow patients to clear their rosacea without side effects such as bruising or skin sensitivity, that are often associated with other treatments.
Dr. Nathan Uebelhoer of the Scripps Clinic treats 30 to 40 rosacea patients per week and recognizes the Vbeam as one of the most effective treatments for rosacea. "Patients are often frustrated and have little hope left by the time they arrive in my clinic," Dr. Uebelhoer said. "Once I treat them with the Vbeam, the majority of my patients wish that they had begun this treatment sooner because of their dramatically enhanced appearance with little downtime. After receiving a series of treatments, patients that were once embarrassed by their condition, have an air of gratitude that makes my role as their doctor extremely rewarding."
The Vbeam works by targeting laser energy to the blood vessels below the epidermis, leaving the superficial layers untouched. Vbeam's technology enables even and consistent delivery of this energy to the underlying vessels, providing a gentle, consistent treatment results that eliminate patient downtime and prevent purpura, or bruising. Vbeam treatments are comfortable and do not require any numbing creams or messy gels during treatment because of the Vbeam's Dynamic Cooling Device® that emits an evaporative cooling spray before each laser pulse increasing safety and patient comfort.
"I have used the Vbeam to treat patients with rosacea on a daily basis for over a decade and have been very impressed with the results," said Dr. Tom Rohrer. "Initially I thought I was just treating the erythema and telangectasia associated with rosacea, but it has become increasingly clear that the Vbeam treatment also has a beneficial effect in treating the disease itself. My patients are not only less red after the treatments, but they maintain their improved appearance and also develop fewer papules. These positive results are usually seen after only two treatments. And, since Vbeam therapy doesn't require patients to remember to take a daily pill or apply a lotion, treatment compliance is high, further contributing to good results. It has been a real breakthrough treatment for people suffering from rosacea," added Dr. Rohrer.
Since many Americans fail to recognize that they have this common skin condition, the National Rosacea Society has designated April as Rosacea Awareness Month to help increase awareness and understanding of this widespread disorder, and to emphasize the importance of seeking medical help. The primary signs of rosacea include redness on the cheeks, nose, chin or forehead; small visible blood vessels on the face; bumps or pimples on the face; and watery or irritated eyes.
For information and educational materials on Rosacea visit: www.rosacea.org
For more information on Candela's Vbeam laser, find a practitioner or to see before and after photos of rosacea treatments with Vbeam, visit http://www.candelalaser.com. Contact Candela at 1-800-733-8550 or via email at firstname.lastname@example.org.
About Vbeam Perfecta:
Vbeam Perfecta features Candela's advanced micro-pulse technology providing consistent and gentle heating, which allows for effective, purpura-free treatment for vascular and epidermal pigmented lesions. Additionally, the digitally enhanced user interface system provides pre-set treatment parameters to allow practitioners to optimize patient treatment results. Vbeam can be used for skin rejuvenation and to help correct a wide range of vascular and pigmented lesions including: rosacea, sun and age spots, face and leg veins, fine lines and wrinkles, port wine stains, hemangiomas, scars, stretch marks, and warts. DCD® is an integrated dynamic cooling device system that automatically emits a cooling spray milliseconds before each pulse to protect the skin, enhance treatment efficacy and increase patient comfort.
About CANDELA: Candela Corporation manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 70 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 18 years ago, and currently has an installed base of 10,000 lasers worldwide. Candela is an Equal Opportunity and Affirmative Action Employer (Male/Female/Handicapped/Veteran). Visit Candela on the Web at http://www.candelalaser.com.
Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, the risk of an adverse judgment in the patent litigation with Palomar Medical Technologies, Inc., (PMTI), successful integration of Inolase, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC, including but not limited to, Candela's Annual Report on Form 10-K for the year ended July 1, 2006, and subsequent Quarterly Reports on Form 10-Q. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.